Should You Buy Optimer Pharmaceuticals, Inc. (OPTR)?
At the moment, there are plenty of metrics investors can use to track their holdings. Two of the most under-the-radar are hedge fund and insider trading interest.
Optimer Pharmaceuticals Inc (OPTR)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 0 | $0 | 0% | ||
| 2. | 40 North Management David S. Winter And David J. Millstone | 0 | $0 | 0% | |
| 3. | Springbok Capital Gavin Saitowitz And Cisco J. Del Valle | 0 | $0 | 0% | |
| 4. | Jet Capital Investors Matthew Mark | 0 | $0 | 0% | |
| 5. | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.08 | 11,000 | Officer | 104,078 | 2012-11-08 | Filing | |
| $7.44 | 5,000 | Director | 5,000 | 2011-08-09 | Filing | |
| $8.98 | 25,000 | Officer, Director | 90,720 | 2011-08-04 | Filing | |
| $10.80 | 8,000 | Officer | 220,396 | 2009-12-29 | Filing | |
| $10.85 | 10,000 | Officer | 212,396 | 2009-12-28 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.73 | 90,000 | Other | 104,078 | 2013-04-08 | Filing | |
| $14.63 | 58,000 | Other | 194,078 | 2013-04-08 | Filing | |
| $15.30 | 3,461 | Director | 102,306 | 2012-06-11 | Filing | |
| $11.75 | 3,461 | Director | 94,806 | 2010-05-12 | Filing | |
| $11.75 | 4,615 | Director | 94,806 | 2010-05-12 | Filing |
News See All
Array Biopharma Inc (ARRY): Hedge Funds Are Bearish and Insiders Are Undecided, What Should You Do?
At the moment, there are many methods investors can use to analyze Mr. Market. Some of the most innovative are hedge fund and insider trading sentiment.
Cubist Pharmaceuticals Inc (CBST), Trius Therapeutics, Inc. (TSRX): How Could This Deal Shake Up an Entire Industry?
With two simultaneous moves that have set the pharmaceutical world on fire, Cubist Pharmaceuticals Inc (NASDAQ:CBST) has triumphantly announced its arrival on the global stage.
Cubist Pharmaceuticals Inc (CBST), Forest Laboratories, Inc. (FRX): Marketed Drugs, Strong Pipeline, Long Term Growth Stock
In June this year, a drug candidate from Cubist Pharmaceuticals Inc (NASDAQ:CBST) received fast track status from the FDA.
Cubist Pharmaceuticals Inc (CBST), Optimer Pharmaceuticals, Inc. (OPTR), Trius Therapeutics, Inc. (TSRX): Will This Biotech Company’s Big Bet Pay Off?
Cubist Pharmaceuticals Inc (NASDAQ:CBST) surged 10% on July 31, after the company acquired two antibiotic makers, Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) and Trius Therapeutics, Inc.
Is Merrimack Pharmaceuticals Inc (MACK) Going to Burn These Hedge Funds?
According to most shareholders, hedge funds are seen as slow, old financial vehicles of the past.
Hedge Funds Are Dumping Optimer Pharmaceuticals, Inc. (OPTR)
Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) was in 11 hedge funds' portfolio at the end of March. OPTR investors should be aware of a decrease in hedge fund interest lately.
MannKind Corporation (MNKD), PDL BioPharma Inc. (PDLI) & Optimer Pharmaceuticals, Inc. (OPTR): 2 Biotechs to Avoid, 1 to Buy
Keeping a close eye on two particular classes of investors can tell you a lot about how stocks might move in the future.
AstraZeneca plc (ADR) (AZN): The Latest News
AstraZeneca plc (ADR) (NYSE:AZN)'s in a tight spot.
Should You Avoid Merrimack Pharmaceuticals Inc (MACK)?
To the average investor, there are a multitude of gauges investors can use to monitor their holdings. Some of the most under-the-radar are hedge fund and insider trading activity.